ALZN Insider Trading

Insider Ownership Percentage: 10.55%
Insider Buying (Last 12 Months): $16,796.99
Insider Selling (Last 12 Months): $0.00

Alzamend Neuro Insider Trading History Chart

This chart shows the insider buying and selling history at Alzamend Neuro by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Alzamend Neuro Share Price & Price History

Current Price: $0.45
Price Change: Price Decrease of -0.11 (-19.49%)
As of 06/14/2024 01:00 AM ET

This chart shows the closing price history over time for ALZN up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Alzamend Neuro Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/19/2024Milton C. Ault IIIDirectorBuy1,000$0.69$690.00771,699View SEC Filing Icon  
4/1/2024Milton C. Ault IIIDirectorBuy334$0.91$303.94770,699View SEC Filing Icon  
1/5/2024Milton C. Ault IIIDirectorBuy5,000$1.02$5,100.00768,365View SEC Filing Icon  
12/26/2023Milton C. Ault IIIMajor ShareholderBuy500$0.90$450.0026,032View SEC Filing Icon  
12/22/2023Milton C. Ault IIIMajor ShareholderBuy200$0.92$184.00166,866View SEC Filing Icon  
9/26/2023David J KatzoffCFOBuy3,533$2.85$10,069.055,400View SEC Filing Icon  
5/24/2023Milton C. Ault IIIMajor ShareholderBuy1,200$8.85$10,620.0025,533View SEC Filing Icon  
4/28/2023Stephan JackmanCEOBuy2,466$8.10$19,974.603,033View SEC Filing Icon  
3/22/2023Lynne Fahey McgrathDirectorBuy666$6.45$4,295.70666View SEC Filing Icon  
3/16/2023Milton C. Ault IIIMajor ShareholderBuy266$7.50$1,995.00737,000View SEC Filing Icon  
2/15/2023Milton C. Ault IIIMajor ShareholderBuy66$9.00$594.00736,733View SEC Filing Icon  
12/27/2022Milton C. Ault IIIMajor ShareholderBuy60$8.85$531.00736,460View SEC Filing Icon  
11/18/2022Milton C. Ault IIIMajor ShareholderBuy66$19.35$1,277.10735,866View SEC Filing Icon  
10/31/2022Milton C. Ault IIIMajor ShareholderBuy400$17.85$7,140.00673,511View SEC Filing Icon  
10/12/2022Milton C. Ault IIIMajor ShareholderBuy133$18.45$2,453.85673,111View SEC Filing Icon  
10/6/2022Milton C. Ault IIIMajor ShareholderBuy66$21.45$1,415.70672,977View SEC Filing Icon  
9/29/2022Milton C. Ault IIIMajor ShareholderBuy233$17.85$4,159.05672,911View SEC Filing Icon  
9/19/2022Stephan JackmanCEOBuy566$18.45$10,442.70566View SEC Filing Icon  
9/14/2022David J KatzoffCFOBuy666$16.65$11,088.901,866View SEC Filing Icon  
8/25/2022Milton C. Ault IIIMajor ShareholderBuy326$14.40$4,694.40667,171View SEC Filing Icon  
8/22/2022Milton C. Ault IIIMajor ShareholderBuy2,400$14.55$34,920.00666,844View SEC Filing Icon  
8/15/2022Milton C. Ault IIIMajor ShareholderBuy933$15.90$14,834.70663,444View SEC Filing Icon  
8/3/2022Milton C. Ault IIIMajor ShareholderBuy133$14.25$1,895.25662,444View SEC Filing Icon  
7/27/2022Milton C. Ault IIIMajor ShareholderBuy380$13.05$4,959.00662,311View SEC Filing Icon  
7/22/2022Milton C. Ault IIIMajor ShareholderBuy153$13.65$2,088.45661,931View SEC Filing Icon  
7/18/2022Milton C. Ault IIIMajor ShareholderBuy666$14.70$9,790.20661,777View SEC Filing Icon  
6/29/2022Milton C. Ault IIIMajor ShareholderBuy666$13.20$8,791.20661,111View SEC Filing Icon  
6/17/2022Milton C. Ault IIIMajor ShareholderBuy666$13.20$8,791.20660,444View SEC Filing Icon  
6/14/2022Milton C. Ault IIIMajor ShareholderBuy666$12.75$8,491.50659,111View SEC Filing Icon  
6/7/2022Milton C. Ault IIIMajor ShareholderBuy133$14.10$1,875.30657,911View SEC Filing Icon  
6/2/2022Milton C. Ault IIIMajor ShareholderBuy533$14.40$7,675.20657,777View SEC Filing Icon  
5/26/2022Milton C. Ault IIIMajor ShareholderBuy666$13.65$9,090.90656,444View SEC Filing Icon  
5/24/2022Milton C. Ault IIIMajor ShareholderBuy1,073$13.35$14,324.55655,777View SEC Filing Icon  
5/17/2022Milton C. Ault IIIMajor ShareholderBuy1,593$14.70$23,417.10654,371View SEC Filing Icon  
5/12/2022Milton C. Ault IIIMajor ShareholderBuy1,666$12.75$21,241.50652,777View SEC Filing Icon  
5/5/2022Milton C. Ault IIIMajor ShareholderBuy6,666$16.05$106,989.3021,666View SEC Filing Icon  
4/26/2022Milton C. Ault IIIMajor ShareholderBuy177,777$22.50$3,999,982.50644,444View SEC Filing Icon  
4/22/2022Milton C. Ault IIIMajor ShareholderBuy5,000$14.10$70,500.0015,000View SEC Filing Icon  
4/11/2022Milton C. Ault IIIMajor ShareholderBuy3,333$16.95$56,494.3510,000View SEC Filing Icon  
3/31/2022Mark GustafsonDirectorSell1,333$18.15$24,193.954,000View SEC Filing Icon  
3/18/2022Milton C. Ault IIIMajor ShareholderBuy6,666$16.50$109,989.00View SEC Filing Icon  
2/24/2022Milton C. Ault IIIMajor ShareholderBuy1,500$17.25$25,875.00View SEC Filing Icon  
1/27/2022Milton C. Ault IIIMajor ShareholderBuy166$21.00$3,486.00View SEC Filing Icon  
1/24/2022Milton C. Ault IIIMajor ShareholderBuy333$19.35$6,443.55View SEC Filing Icon  
1/18/2022Milton C. Ault IIIMajor ShareholderBuy466$24.90$11,603.40View SEC Filing Icon  
1/14/2022Milton C. Ault IIIMajor ShareholderBuy200$26.85$5,370.00View SEC Filing Icon  
1/7/2022Milton C. Ault IIIMajor ShareholderBuy200$28.95$5,790.00View SEC Filing Icon  
1/5/2022Milton C. Ault IIIMajor ShareholderBuy133$29.70$3,950.10View SEC Filing Icon  
12/23/2021Milton C. Ault IIIMajor ShareholderBuy107$31.50$3,370.50View SEC Filing Icon  
12/20/2021Milton C. Ault IIIMajor ShareholderBuy1,666$31.65$52,728.90View SEC Filing Icon  
12/17/2021Milton C. Ault IIIMajor ShareholderBuy866$37.20$32,215.20View SEC Filing Icon  
12/14/2021Mark GustafsonDirectorSell1,333$42.75$56,985.75View SEC Filing Icon  
11/30/2021Milton C. Ault IIIMajor ShareholderBuy354$34.05$12,053.70View SEC Filing Icon  
11/22/2021Milton C. Ault IIIMajor ShareholderBuy1,000$28.50$28,500.00View SEC Filing Icon  
11/8/2021Milton C. Ault IIIMajor ShareholderBuy9,666$38.55$372,624.30View SEC Filing Icon  
9/14/2021Milton C. Ault IIIMajor ShareholderBuy333$40.50$13,486.5010,000View SEC Filing Icon  
8/27/2021Milton C. Ault IIIMajor ShareholderBuy400$43.50$17,400.00View SEC Filing Icon  
8/17/2021Milton C. Ault IIIMajor ShareholderBuy266$49.35$13,127.10View SEC Filing Icon  
8/12/2021Milton C. Ault IIIMajor ShareholderBuy226$58.05$13,119.30View SEC Filing Icon  
8/9/2021Milton C. Ault IIIMajor ShareholderBuy33$60.75$2,004.75View SEC Filing Icon  
8/6/2021Milton C. Ault IIIMajor ShareholderBuy266$61.05$16,239.30View SEC Filing Icon  
8/4/2021Milton C. Ault IIIMajor ShareholderBuy33$64.50$2,128.50View SEC Filing Icon  
8/2/2021Milton C. Ault IIIMajor ShareholderBuy100$68.40$6,840.00View SEC Filing Icon  
7/30/2021Milton C. Ault IIIMajor ShareholderBuy89,222$22.65$2,020,878.30View SEC Filing Icon  
7/26/2021Milton C. Ault IIIMajor ShareholderBuy233$74.10$17,265.30View SEC Filing Icon  
7/23/2021Milton C. Ault IIIMajor ShareholderBuy333$86.40$28,771.20View SEC Filing Icon  
7/19/2021Milton C. Ault IIIMajor ShareholderBuy266$81.15$21,585.90View SEC Filing Icon  
7/16/2021Milton C. Ault IIIMajor ShareholderBuy40$93.45$3,738.00View SEC Filing Icon  
7/14/2021Milton C. Ault IIIMajor ShareholderBuy333$101.10$33,666.30View SEC Filing Icon  
7/12/2021Milton C. Ault IIIMajor ShareholderBuy540$92.25$49,815.00View SEC Filing Icon  
7/8/2021Milton C. Ault IIIMajor ShareholderBuy133$91.20$12,129.60View SEC Filing Icon  
7/6/2021Milton C. Ault IIIMajor ShareholderBuy466$106.05$49,419.30View SEC Filing Icon  
6/28/2021Milton C. Ault IIIMajor ShareholderBuy600$144.15$86,490.00View SEC Filing Icon  
6/25/2021Milton C. Ault IIIMajor ShareholderBuy933$131.85$123,016.05View SEC Filing Icon  
6/22/2021Milton C. Ault IIIMajor ShareholderBuy4,933$139.35$687,413.55
See Full Table

SEC Filings (Institutional Ownership Changes) for Alzamend Neuro (NASDAQ:ALZN)

49.61% of Alzamend Neuro stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ALZN by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Alzamend Neuro Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
5/20/2024Virtu Financial LLC26,482$26K0.0%N/A0.385%Search for SEC Filing on Google Icon
2/2/2024Truist Financial Corp154,327$0.14M0.0%-93.3%2.168%Search for SEC Filing on Google Icon
5/11/2022RFG Advisory LLC250,000$0.31M0.0%N/A0.277%Search for SEC Filing on Google Icon
5/9/2022Qube Research & Technologies Ltd78,465$97K0.0%N/A0.087%Search for SEC Filing on Google Icon
4/22/2022Truist Financial Corp2,314,907$2.85M0.0%N/A2.569%Search for SEC Filing on Google Icon
1/31/2022Commonwealth Equity Services LLC116,666$0.22M0.0%N/A0.131%Search for SEC Filing on Google Icon
11/16/2021Schonfeld Strategic Advisors LLC31,600$97K0.0%N/A0.036%Search for SEC Filing on Google Icon
11/16/2021Two Sigma Investments LP172,913$0.53M0.0%N/A0.199%Search for SEC Filing on Google Icon
11/16/2021Warberg Asset Management LLC14,000$43K0.0%N/A0.016%Search for SEC Filing on Google Icon
11/15/2021Sassicaia Capital Advisers LLC93,762$0.29M0.8%N/A0.108%Search for SEC Filing on Google Icon
9/17/2021Virtu Financial LLC15,402$0.14M0.0%N/A0.018%Search for SEC Filing on Google Icon
8/16/2021Cubist Systematic Strategies LLC23,672$0.21M0.0%N/A0.028%Search for SEC Filing on Google Icon
8/13/2021Geode Capital Management LLC44,600$0.39M0.0%N/A0.052%Search for SEC Filing on Google Icon
8/11/2021Susquehanna International Group LLP57,030$0.50M0.0%N/A0.067%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Alzamend Neuro logo
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Read More on Alzamend Neuro

Today's Range

Now: $0.45
Low: $0.44
High: $0.51

50 Day Range

MA: $0.65
Low: $0.45
High: $0.91

52 Week Range

Now: $0.45
Low: $0.44
High: $10.65


164,490 shs

Average Volume

70,634 shs

Market Capitalization

$3.35 million

P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of Alzamend Neuro?

Alzamend Neuro's top insider shareholders include:
  1. Milton C Ault III (Director)
  2. Milton C Ault III (Major Shareholder)
  3. David J Katzoff (CFO)
  4. Stephan Jackman (CEO)
  5. Lynne Fahey Mcgrath (Director)
Learn More about top insider investors at Alzamend Neuro.

Who are the major institutional investors of Alzamend Neuro?

Alzamend Neuro's top institutional shareholders include:
  1. Virtu Financial LLC — 0.38%
  2. Concourse Financial Group Securities Inc. — 0.00%
Learn More about top institutional investors of Alzamend Neuro stock.

Which institutional investors are buying Alzamend Neuro stock?

During the previous quarter, ALZN stock was purchased by institutional investors including:
  1. Virtu Financial LLC
In the last year, these company insiders have bought Alzamend Neuro stock:
  1. Milton C Ault III (Director)
  2. Milton C Ault III (Major Shareholder)
  3. David J Katzoff (CFO)
  4. Stephan Jackman (CEO)
  5. Lynne Fahey Mcgrath (Director)
Learn More investors buying Alzamend Neuro stock.